CLAIMS

1. An association of the active principles:

a) the xanthine oxidase inhibitor, febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof; and

b) ~~one or more~~the HMG CoA reductase inhibitor~~s~~ atorvastatin ~~belonging to the class of statins~~ or pharmaceutically acceptable salts thereof

for use in a human or veterinary therapeutic treatment.

2. The association according to claim 1, wherein said active principle (a) is associated to the active principle (b) in a weight ratio comprised between 0.1 and 200.

3. The association according to claim 2, wherein said weight ratio is comprised between 0.6 and 10.

~~4. The association according to any one of claims 1 to 3, wherein said HMG CoA reductase inhibitor is selected from the group comprising: atorvastatin, cerivastatin, fluvastatin, levostatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or pharmaceutically acceptable salts thereof.~~

~~5~~4. The association according to any one of claims 1 to 43, wherein said HMG CoA reductase inhibitor is atorvastatin calcium.

~~6~~5. The association according to any one of claims 1 to ~~5~~4, for use in the therapeutic treatment of hypercholesterolemia.

~~7~~6. The association according to any one of claims 1 to ~~6~~5, for use in the therapeutic treatment of hypercholesterolemia associated to hyperuricemia and/or hyperglycemia.

~~8~~7. The association according to any one of claims 1 to ~~7~~6, for use in the therapeutic treatment of hypercholesterolemia associated to hyperuricemia and/or hyperglycemia in the context of the metabolic syndrome.

~~9~~8. The association according to any one of claims 1 to ~~6~~5, for use in the therapeutic treatment of hypercholesterolemia and associated to disorders of the metabolic syndrome.

~~10~~9. A pharmaceutical composition for use in a human or veterinary therapeutic treatment comprising, as active principle, a mixture of:

a) the xanthine oxidase inhibitor, febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof; and

b) ~~one or more~~the HMG CoA reductase inhibitor~~s~~ atorvastatin ~~belonging to the class of statins~~ or pharmaceutically acceptable salts thereof

one or more pharmaceutically acceptable excipients and/or additives and/or diluents.

~~11. The pharmaceutical composition according to claim 10, wherein said HMG CoA reductase inhibitor is selected from the group comprising: atorvastatin, cerivastatin, fluvastatin, levostatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or pharmaceutically acceptable salts thereof.~~

~~12~~10. The pharmaceutical composition according to any one of claims ~~10 or 11~~9, wherein said HMG CoA reductase inhibitor is atorvastatin calcium.

~~13~~11. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~12~~10, for use in the therapeutic treatment of hypercholesterolemia.

~~14~~12. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~13~~11, for use in the therapeutic treatment of hypercholesterolemia associated to hyperuricemia and/or hyperglycemia.

~~15~~13. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~14~~12, for use in the therapeutic treatment of hypercholesterolemia associated to hyperuricemia and/or hyperglycemia in the context of the metabolic syndrome.

~~16~~14. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~15~~13, for use in the therapeutic treatment of hypercholesterolemia associated to other disorders of the metabolic syndrome.

~~17~~15. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~16~~14, wherein said xanthine oxidase inhibitor, febuxostat, is in an amount comprised between 10-200 mg per dosage unit.

~~18~~16. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~17~~15, wherein said xanthine oxidase inhibitor, febuxostat, is in an amount comprised between 25-100 mg per dosage unit.

~~19~~17. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~18~~16, wherein said HMG CoA reductase inhibitor is in an amount comprised between 1.0-100 mg per dosage unit.

~~20~~18. The pharmaceutical composition according to any one of claims ~~10~~ 9 to ~~19~~17, wherein said HMG CoA reductase inhibitor is in an amount comprised between 10-40 mg per dosage unit.

~~21~~19. A method for the preparation of the composition according to any one of claims ~~10~~ 9 to ~~20~~18, wherein the active mixture comprising:

a) the xanthine oxidase inhibitor, febuxostat, or pharmaceutically acceptable salts thereof or polymorphic forms thereof; and

b) ~~one or more~~ the HMG CoA reductase inhibitor~~s~~ atorvastatin ~~belonging to the class of statins~~ or pharmaceutically acceptable salts thereof

is formulated in suitable dosage units with one or more pharmaceutically acceptable excipients and/or additives.